An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/23/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/22/2025
|
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/21/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/20/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/19/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/18/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/17/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/16/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/15/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/14/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/13/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/12/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/11/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/10/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/09/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/08/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/07/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 02/05/2025
|
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 02/04/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/03/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/02/2025
|
INVESTOR ALERT: XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 02/01/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 02/01/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/31/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/30/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/30/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/29/2025
|
XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/29/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/28/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/28/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/27/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/27/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/26/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/26/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/26/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/25/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/24/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/24/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/24/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/23/2025
|
XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/23/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/22/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/22/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/22/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/21/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/21/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/20/2025
|
XBIT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into XBiotech Inc. and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/20/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/19/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/19/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/18/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/18/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/17/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/17/2025
|
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , Jan. 17, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ: XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/17/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/16/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/16/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/16/2025
|
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/15/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/15/2025
|
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
- PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
- 01/14/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
- 01/14/2025
|
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/14/2025
|
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.
- LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 01/13/2025
|
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm.
- 01/13/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/12/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/10/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/08/2025
|
Shareholders that lost money on XBiotech Inc.(XBIT) should contact Levi & Korsinsky about Securities Fraud Investigation - XBIT
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/08/2025
|
Lost Money on XBiotech Inc.(XBIT)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/07/2025
|
XBIT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/05/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/05/2025
|
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/03/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/03/2025
|
Lost Money on XBiotech Inc. (XBIT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/02/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/02/2025
|
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 01/02/2025
|
XBiotech Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - XBIT
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/31/2024
|
Shareholders that Lost Money on XBiotech Inc. (XBIT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - XBIT
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/30/2024
|
An Investigation Has Commenced on Behalf of XBiotech Inc. Shareholders. Contact Levi & Korsinsky to Discuss your XBIT Losses.
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/29/2024
|
XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/27/2024
|
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - XBIT
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/26/2024
|
XBIT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
- 12/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/24/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/23/2024
|
XBiotech Pauses Rheumatology program
- Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
- 12/23/2024
|
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
- Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.
- 06/18/2024
|
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
- Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
- 06/18/2024
|
XBiotech: Several Shots On Goal In Big Target Market Indications
- XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis. While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
- 05/24/2024
|
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
- Two microcap biotech stocks to consider for the science-challenged among us.
- 03/07/2024
|
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
- AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.
- 01/04/2024
|
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
- (Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation)
- 11/14/2023
|
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
- AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin.
- 09/26/2023
|
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
- AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.
- 08/30/2023
|
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
- AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).
- 08/08/2023
|
Why Are XBiotech Shares Trading Higher Today
- The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs.
- 04/28/2022
|
XBiotech Announces Payment of Dividend to Holders of Common Stock
- Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
- 07/30/2021
|
XBiotech Stock Increased 7.41%: Why It Happened
- The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.
- 07/07/2021
|
XBiotech Announces Dividend to Holders of Common Stock
- AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021.
- 07/06/2021
|
XBiotech Announces Receipt of $75 Million from Sale of Antibody
- Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
- 06/30/2021
|
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
- XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment
- 06/23/2021
|
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
- The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotech's new drug and assess the tolerability of the combination at escalating doses.
- 04/19/2021
|
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
- XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
- 04/19/2021
|
Top Small-Cap Stocks for March 2021
- These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.
- 02/26/2021
|
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
- With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain
- 01/21/2021
|
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
- Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D.
- 01/19/2021
|
XBiotech: New Q1 2021 Clinical Announcement, 9M 2020 Confirmed Short-Term Janssen Revenues, 2022 Is Uncertain, +28% Upside
- XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candidates with 3 in the pre-clinical phase. Starting 1-2Q 2021, XBiotech aims to re-enter the clinic with more than one new anti-IL-1a therapy.
- 11/19/2020
|
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
- Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential
- 11/19/2020
|
5 Ben Graham Lost Formula Stocks With High Financial Strength
- As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Perdoceo Education Corp. (NASDAQ:PRDO) according to the All-in-One Screener, a Premium feature of GuruFocus.
- 10/28/2020
|
